Cogent Biosciences Announces Positive Updated Lead-in Data From Ongoing Phase 3 Peak Trial Evaluating Bezuclastinib in Combination With Sunitinib in Patients With Gastrointestinal Stromal Tumors (Gist) at Asco Annual Meeting
Cogent Biosciences在Asco年會上公佈了正在進行的評估Bezuclastinib與舒尼替尼聯合治療胃腸道間質瘤患者（Gist）的3期高峰期試驗的積極更新前導數據